Drug intelligence / Profile preview

aspergillopepsin-2

Development stage
Unknown
Modality
Therapeutic Enzymes → Recombinant Proteins and Enzymes
Administration
Oral (as Digestive Supplement)
01

Overview

Aspergillopepsin-2 is a proteolytic enzyme isolated from the fungus Aspergillus niger var. macrosporus[2][3][8]. It was previously classified as an aspartic protease but is now recognized as a glutamic protease with a catalytic glutamic acid residue at its active site[2][8]. The enzyme consists of two non-covalently bound chains (light and heavy), and its C-terminal region can bind to the active site cleft of another molecule in a substrate-like manner[2]. Aspergillopepsin-2 preferentially cleaves peptide bonds in proteins such as insulin at specific sites (e.g., Asn-Gln, Gly-Ala, Tyr-Thr)[2]. It belongs to the peptidase family G1 and is used industrially for its potent protein-digesting activity; it also has applications in food processing and dietary supplements for aiding digestion[4][5].

Other names
aspergilloglutamic peptidaseAspergillus niger acid proteinase AAspergillus niger var. macrosporus aspartic proteinase

Beyond the preview

Go deeper on aspergillopepsin-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on aspergillopepsin-2.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call